2018
A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)
Kamenicky P, Lachmann R, Carpenter T, Cohen-Solal M, Eastell R, Brandi M, Crowley R, Ralston S, Javaid M, Keen R, Briot K, Il C, Imanishi Y, Ito N, Tanaka H, Zhang L, Theodore-Oklota C, Mealiffe M, Martin J, Insogna K. A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH). Endocrine Abstracts 2018 DOI: 10.1530/endoabs.56.oc3.1.Peer-Reviewed Original Research
2014
A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia
Carpenter T, Imel E, Ruppe M, Weber T, Klausner M, Wooddell M, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock M. A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia. Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp90.Peer-Reviewed Original ResearchPharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia
Zhang X, Carpenter T, Imel E, Ruppe M, Weber T, Klausner M, Kawakami T, Ito T, Humphrey J, Insogna K, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia. Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp91.Peer-Reviewed Original Research
1989
Osteoblast-Like Cells Secrete Granulocyte-Macrophage Colony-Stimulating Factor in Response to Parathyroid Hormone and Lipopolysaccharide*
WEIR EC, INSOGNA KL, HOROWITZ MC. Osteoblast-Like Cells Secrete Granulocyte-Macrophage Colony-Stimulating Factor in Response to Parathyroid Hormone and Lipopolysaccharide*. Endocrinology 1989, 124: 899-904. PMID: 2643512, DOI: 10.1210/endo-124-2-899.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell DivisionCell LineColony-Stimulating FactorsDNA ReplicationGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesInterleukin-2Interleukin-3Interleukin-4InterleukinsKineticsLipopolysaccharidesOsteoblastsOsteosarcomaParathyroid HormoneRatsRecombinant ProteinsThymidineConceptsGranulocyte-macrophage colony-stimulating factorInterleukin-2GM-CSF antibodyIL-4Colony-stimulating factorMitogenic activityCSF antibodiesROS cellsGM-CSFT-cell mitogenic activityPresence of antibodiesDose-dependent increaseHT-2 cellsBone resorptionOsteoblast-like cellsOsteoclast precursorsPTHCell CMLipopolysaccharideAntibodiesCellular mechanismsEffect of incubationCytokinesBiochemical criteriaCSF